Member Info for evman27

I also asked, Could the company see a scenario where the NCI sign a continuation deal to continue using Optimal?

There was no response, one could speculate that there is currently negotiations going on with the NCI...

Comments from Adrian fresh from the investor hub.

‘We can’t comment on individual clients or conversations we might have had with them for obvious reasons. We can confirm that there is interest in the marketplace and we are hopeful that this will lead to a vibrant successful future for OptiMAL®, the related platforms and for Fusion as well as our stakeholders.’

Tree shake

Wouldn’t want to be out of this over the weekend!

This is a great start but the journey is far from over.

When the good news lands and Adrian’s sleeves burst open, woah, buckle up folks.

Hold for gold.

As my astute friend Vick would say.

Stay vested 😎

Market finally starting to wake up.

Great day, great start.

Fusions library is 10^45

In long form, 1000000000000000000000000000000000000000000000

Rather impressive library compared to our competitors who sit around 10^8 - 10^15

MMs have no stock, this could move big day on some volume

Screw the MMs.

Big delayed buys printing as sells, keep the momentum going FABbers.

Last week I asked Adrian about AGM dates and further investor relations, he said the following.

‘We are also planning some other investor days which may be more informative and convenient for Q&A. We expect this to include an on-line presentation in line with other years as well as at least two other investor presentations.’

‘Furthermore we are considering an option of a further presentation in Belfast for our more local stakeholders and interested parties. We hope that this will provide plenty of opportunities for investors to hear all the latest news and opportunities to delve further into the details.’

This is really exciting, the company is seriously gearing up the PR, the patent granted today secures the technology and the coming months should be full of riveting promotion.

‘In the meantime, the patent is a significant value add to our IP portfolio, immediately adding value to the company.’ CEO Adrian

You would be mad to sell at this inflection point

Fantastic to email Adrian in the morning asking for some answers to questions on the Hub and for him to get back to shareholders quickly with in-depth answers later that day.

I strongly encourage shareholders to read the answers on the hub and to ask any questions.

The future looks FAB!

Bit of a slow day but shareholders know what they own and happy to hold

Apart from Mr 50k! There is always one…

Anyone else excited for this week coming?!

AI is quickly becoming a core business function for competitive advantage amongst all sectors. Fusion Antibodies is well aware of this shift and their platforms take advantage of this new technology.

Fusion Antibodies is currently using AI to

• Improve developability of therapeutic antibodies (e.g., solubility, aggregation resistance, stability).

• Predict liability regions (such as potential immunogenicity or poor expression).

• Suggest mutations to enhance properties like binding affinity or reduce manufacturability risks.

They currently offer a proprietary "AI-powered humanization platform" called RAMPTM (Rapid Antibody Maturation Platform), which:

• Uses AI to predict optimal humanization strategies while preserving antigen binding.

• Reduces immunogenicity of non-human antibodies.

• Speeds up time-to-clinic by automating parts of the design process.

Dr. Richard Buick, PhD, Chief Scientific Officer at Fusion Antibodies plc delivered a presentation at the Discovery on Target conference, held September 30 - October 3, 2024

The presentation introduced the AI/ML Ab™ service—a platform combining in silico AI/ML driven antibody sequence design with Fusion’s established Mammalian Display and antibody evaluation capabilities.

AI partners design large libraries of novel antibody sequences. Instead of traditional low-throughput screening, these libraries are produced and screened using Fusion’s OptiMAL®–powered Mammalian Display system, enabling highly efficient selection of top candidates.

Wouldn't want to be out of this over the weekend!!

Agreed gents, hopefully that opens the floodgates (Sleeves).

Well said Cheapsharesboy.

You won't be able to buy these cheap for long!

Here are a couple of examples of external grants and funding and why Fusion should not need to raise capital.

Infrastructure Support via the Future Medicines Institute (FMI)

As of 2025, Fusion is a core industrial partner in Queen’s new Future Medicines Institute (FMI), part of the NIPBT Consortium funded by UKRI and Invest NI.

* Date announced: 4 December 2024

* Fusion’s funded role: As a NIPBT member, Fusion has access to

* £1 million in direct, non‑dilutive R&D funding over up to five years

* Access to £5 million in capital equipment, including state-of-the-art bioprocessing and protein engineering platforms housed within QUB facilities

* Approximately 20 core staff, lab facilities, and PhD studentships via the Future Medicines Institute at Queen’s University Belfast

* Project start: 1 January 2025

Innovate UK Launchpad Grant – Anti‑DR5 therapeutic antibody

* Date announced: 24 April 2025

* Fusion’s funding: Up to £545,000 direct grant, as part of a total project package (~£808k)

* Project duration: ~18 months, starting from 1 May 2025

* Objective: Develop a humanised DR5-agonist antibody targeting treatment‑resistant cancers; joint ownership with Queen’s University Belfast